LMLisa M. Matz

Lisa M. Matz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa M. Matz has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microbiome‐associated metabolic determinants of neurodegeneration and cognitive resilience

    by Lisa M Matz, Nisarg S. Shah, Randall J Urban, Rakez Kayed, Shelly A Buffington

    Background: Type 2 diabetes (T2D) is a common antecedent of pathological neurodegeneration and accompanying dementia, including Alzheimer’s Disease (AD); however, the mechanistic link between metabolic and neurodegenerative disorders remains unresolved (1‐3). Study of a small cohort of dementia patients revealed divergent gut microbiota composition, increased gut permeability, and inflammation, implicating a microbial determinant in neuroimmune dysregulation (4), an emerging player in neurodegeneration (5). Notably, the microbiome is a source of neuroprotective metabolites (6), highlighting the need to elucidate the role of the microbiome and realize the potential for its therapeutic modulation in AD. We recently began a clinical trial focusing on individuals of Mexican descent living in Southern Texas, a population with increased prevalence of co‐morbid T2D and early onset AD (7‐8), with the working hypothesis that diet‐driven shifts in gut microbiome composition contribute to T2D and AD pathophysiology in this population (9‐11).Method: We will perform metagenomic 16S rRNA gene amplicon sequencing and compare within (alpha) and between (beta) sample diversity as well as quantitative phylogenetic and taxonomic comparisons. Using 3xTg‐AD and hTau mouse models, we will determine the impact of microbial depletion via broad spectrum antibiotics on AD pathology and cognitive function. Data will be analyzed separately for each sex using nested t‐tests, nested one‐way ANOVA, or a mixed effects model to account for litter effects.Result: Data resulting from our preclinical animal and clinical human studies will inform future experiments in which we will transplant fecal microbiota samples derived from T2D versus non‐diabetic human subjects into microbially‐depleted, “humanized” AD mice. We will then perform metabolomic, molecular, electrophysiological, and behavioral analyses to determine the impact(s) of T2D gut microbiota on host AD‐like pathology and behavioral phenotypes.Conclusion: Characterizing gut microbiome signatures of T2D individuals of Mexican descent living in Southern Texas could identify key actors among “disease state” microbiota which may exacerbate or accelerate neurodegenerative disorders, as well as gut microbiota present in healthy controls lost in the T2D population which contribute to molecular mechanisms of cognitive resilience. Consequently, our approach may lead to novel immunotherapeutic approaches to target or limit neuroinflammation in AD.

  • Open Access

    A study of innate immune kinetics reveals a role for a chloride transporter in a virulent Francisella tularensis type B strain

    by Lisa M. Matz, Joseph F. Petrosino

    Tularemia is a zoonotic disease of global proportions. Francisella tularensis subspecies tularensis (type A) and holarctica (type B) cause disease in healthy humans, with type A infections resulting in higher mortality. Repeated passage of a type B strain in the mid‐20th century generated the Live Vaccine Strain (LVS). LVS remains unlicensed, does not protect against high inhalational doses of type A, and its exact mechanisms of attenuation are poorly understood. Recent data suggest that live attenuated vaccines derived from type B may cross‐protect against type A. However, there is a dearth of knowledge regarding virulent type B pathogenesis and its capacity to stimulate the host's innate immune response. We therefore sought to increase our understanding of virulent type B in vitro characteristics using strain OR96‐0246 as a model. Adding to our knowledge of innate immune kinetics in macrophages following infection with virulent type B, we observed robust replication of strain OR96‐0246 in murine and human macrophages, reduced expression of pro‐inflammatory cytokine genes from “wild type” type B‐infected macrophages compared to LVS, and delayed macrophage cell death suggesting that virulent type B may suppress macrophage activation. One disruption in LVS is in the gene encoding the chloride transporter ClcA. We investigated the role of ClcA in macrophage infection and observed a replication delay in a clcA mutant. Here, we propose its role in acid tolerance. A greater understanding of LVS attenuation may reveal new mechanisms of pathogenesis and inform strategies toward the development of an improved vaccine against tularemia.


  • Challenges of Francisella classification exemplified by an atypical clinical isolate

    by Lm Matz, Ky Kamdar, Me Holder, Ga Metcalf, Gm Weissenberger, Q Meng, V Vee, Y Han, Dm Muzny, Ra Gibbs, et al.


  • Open Access

    Universal microbial diagnostics using random DNA probes

    by Amirali Aghazadeh, Adam Y. Lin, Mona A. Sheikh, Allen L. Chen, Lisa M. Atkins, Coreen L. Johnson, Joseph F. Petrosino, Rebekah A. Drezek, Richard G. Baraniuk

    A new diagnostic platform based on randomized DNA probes can screen for common human pathogens.